Westlake Village BioPartners — Full Portfolio

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)

Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.

BiotechDeep TechDigital HealthMedical Devices

Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)

Co-investorsVersant Ventures

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

BiotechHealthtechBoulder, US

Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)

BoardAmit Mehta(Director)

Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025

Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorBoxOne Ventures+1 more

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Ken Drazan(Founder)James Ahlers(Executive Officer)Kenneth Drazan(Executive Officer, Director)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)

BoardValentin Barsan(Director)

Board seatBeth Seidenberg· per SEC Form D

Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsOUP (Osage University Partners)SoftBank Vision Fund

HealthtechSeattle, US

John D. Hoekman(Executive Officer, Director)

BoardMichael Hite(Director)Stewart Parker(Director)

Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021

Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners

Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.

BiotechHealthtechThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

BoardJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)

Board seatBeth Seidenberg· per SEC Form D · $150M raise · filed Feb 2025

Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi Ventures5AM Ventures

NeuroGastrx is a company in the gastrointestinal/neurogastroenterology therapeutics space.

BiotechHealthtechWoburn, US

Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)

Board seatDavid Allison· per SEC Form D · filed Jul 2021

Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global Strategic

BiotechSan Francisco, US

Kristine M Ball(Executive Officer, Director)Zachary Hill(Executive Officer, Director)

BoardNisha Marathe(Director)Keno Gutierrez(Director)David Morris(Director)

Board seatDavid Allison· per SEC Form D · $42.2M raise · filed May 2021

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

Adam Rosenthal(Founder & CEO)inJason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)

Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025

Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more

3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.

AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US

K. Christopher GarciaMarvin Gee(Founder)in

Co-investorsAsset Management CompanyCRV (Charles River Ventures)Menlo VenturesOS FundStarlight Ventures

Clinical stage company developing a small molecule pan-ROCK inhibitor targeting pulmonary and fibrotic indications.

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.

BiotechNatick, US

Catherine Pearce(CEO & Founder)Catherine J. Pearce(Founder)DHSc(Founder)Justin R Thompson(Founder)

Co-investorsVersant VenturesWestlake BioPartners

A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.

Borealis develops RNA medicines to treat kidney diseases.

BiotechDigital Health

A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)

BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)

Co-investorsOrbiMedRA CapitalNVIDIA

A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.

BiotechSan Diego, US

Kevin Forrest, Ph.D.(Executive Officer, Director)

BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)

Co-investorsOsage University PartnersVersant Ventures

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.

Biotech

Co-investorsVida Ventures

Clinical-stage biotech developing non-opioid pain medicines targeting pain transduction.

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.

AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US

Nancy Stagliano(CEO)in

Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision Fund

Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.

BiotechHealthtech

Sujay Kango(Chief Executive Officer & Founder)Janethe Pena(Chief Medical Officer & Founder)inConnie Coulomb(Chief Business Officer & Founder)

Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.

AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US

Nancy Whiting(CEO)

Co-investorsAccess BiotechnologyNew Enterprise Associates (NEA)

Biotech developing therapies for rare diseases.

Cell therapy company now part of Kite, a Gilead Company, focused on treating cancer.

Preclinical stage company developing next-generation biologics for migraine prevention.

Clinical stage biotech developing first-in-class therapies for rare blood disorders, starting with von Willebrand disease.